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Introduction
It is clear from the presentations at this symposium that
Assisted Reproductive Technologies (ARTs) in nonhuman
primates have made substantial progress since 1984,
when the first reports appeared of successful births follow-
ing in vitro fertilization (IVF) [1,2]. It can truly be said that
nonhuman primate ARTs have "come of age" because
these births occurred 21 years ago (Figure 1). Initial
research efforts were almost entirely directed at establish-
ing appropriate culture conditions for in vitro production
(IVP) of monkey embryos, and subsequently at devising
workable embryo transfer techniques. The latter efforts
illustrate one of the significant differences between
macaque and human IVP in its broadest sense (embryo
production and births). Although several species of non-
human primate have been used to study ARTs, the great
majority of studies have been with the rhesus macaque,
Macaca mulatta, because it is (or was) widely available
and because of its general similarity to humans. However,
with the heavy emphasis on the use of rhesus monkeys for
AIDS-related research during the past ten years, limited
availability of animals is restricting reproductive research
efforts, almost to the point of blocking research in some
cases.
Until recently, the primary rationale for ARTs research
with nonhuman primates has been to provide informa-
tion and new technologies that could assist human ARTs.
Because basic research, and to some extent the develop-
ment of new technologies, cannot or should not be done
on humans, the nonhuman primate model ought to play
a central role in these efforts. Paradoxically, this role to
date has been minimal, for several reasons. First, human
ART (IVF/IVP/ET) was established before ART in nonhu-
man primates. Human ART has been developing since
1969, when the first IVF was reported [3], culminating in
the birth of Louise Brown in 1978, five years before the
first nonhuman primate IVF births. Because of the social
importance and commercialization of human ART, it has
progressed much faster than nonhuman primate ART.
This has made it difficult to present the case for nonhu-
man primate ART as a model for human ART, because the
former is usually perceived as playing "catch-up" to the
latter. Second, nonhuman primate ART presently owes
more to human ART than vice-versa, e.g., the develop-
ment and availability of human recombinant gonadotro-
pins, without which monkey ART would be very difficult
and perhaps prohibitively expensive. As a result, there has
been very little technology transfer from basic research
with nonhuman primates to the human clinical arena.
Nevertheless, there are several key areas in which progress
in human ART has virtually stalled, and quantum
improvements in ART success will need new information
and technology that can only be obtained using suitable
experimental animal models, i.e., nonhuman primates.
The efficiency of human ART is rather low – on average,
about 12% per embryo transferred, and <5% per embryo
produced [4,5]. Improvements could be made, for exam-
ple, by devising even better culture media for IVP and
objective methods for selecting the most viable embryos
for transfer. Moreover, as this symposium demonstrates,
there is great potential for nonhuman primate ART to
make a major contribution to embryonic stem cell biol-
ogy and technology, avoiding difficult ethical and logisti-
cal problems inherent in human ES cell studies and
applications.
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"Petri," the first IVF macaque monkey, shown here at about 5 years of age. He has since fathered numerous normal 
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and most of the technical problems have been resolved, it
is now timely to directly apply it to solving problems in
human infertility and stem cell research. That is why this
symposium is most opportune.
Gamete collection and processing
Methods for collecting semen from rhesus macaques are
well established, and have been in use for the past 20 years
at some of the National Primate Centers. The most com-
mon method involves penile electrical stimulation, which
yields spermatozoa that are highly motile and capable of
IVF. One disparity between macaque and human sperma-
tozoa is that the former need chemical activators (caffeine
and dbcAMP) to complete capacitation and support func-
tional acrosome reactions, whereas human spermatozoa
require no specific activators. The need for chemical stim-
ulation of rhesus monkey spermatozoa allows the acqui-
sition of fertilizing ability to be precisely controlled,
which is useful for IVF and for basic research, but it also
makes macaque spermatozoa less useful as a model for
human spermatozoa.
Oocyte collection in nonhuman primates is obviously
more labor-intensive than semen collection. Collection of
oocytes is done routinely after ovarian stimulation, usu-
ally with human recombinant gonadotropins. Availability
of these hormones has revolutionized nonhuman primate
ART because each female can usually be stimulated four or
five times before becoming refractory. Previously, when
using natural hormones (e.g., human urinary FSH,
human chorionic gonadotropin, equine chorionic gona-
dotropin) animals became refractory after only one cycle
of stimulation [6], which meant that a fresh female had to
be used for every cycle, and this made nonhuman primate
ART prohibitively expensive. Most primate centers still use
laparoscopic aspiration of stimulated follicles, which is
quite effective, but it is a tedious procedure and some-
times follicles are difficult to access. A faster and more effi-
cient route is by ultrasound-guided aspiration, as in
women, but this requires a much higher level of skill by
the operator. At present, it appears that only one primate
center is using this procedure routinely, and its use should
be adopted in other centers.
The term "controlled ovarian stimulation" was used by
some investigators, but this raised the question: is it really
controlled? The doses of gonadotropins, especially of
FSH, given to rhesus monkeys are very high, about 2–10
times the dose administered to women on a body weight
basis. The possibility that such high gonadotropin doses
interfere with the proper development of follicles and
oocytes needs investigation. It seems likely that some
defective follicles and oocytes that may be destined for
atresia are being recruited. The standard "one ampoule
per day" regimen of FSH given to a monkey has not been
adequately examined to find if lower doses might be effec-
tive. It is possible that lower doses might produce accept-
able outcomes, perhaps with fewer oocytes having a
higher overall quality.
Another important question is the number of cycles of
ovarian stimulation allowed on each monkey, which is up
to the IACUC at each primate center. There does not
appear to be any objective rationale for the number(s) of
stimulation cycles allowed. Some Animal Use Commit-
tees permit six or more cycles, while others are more con-
servative. It would be helpful if guidance could be
obtained from NIH and/or USDA to determine what is a
reasonable number of cycles per donor, and to standard-
ize this across the primate centers. It does not appear that
repeated ovarian stimulation with exogenous gonadotro-
pins harms the females' fertility or capacity to bear off-
spring. Raising the number of cycles permitted could
significantly reduce the numbers of animals needed for a
research study, and thereby substantially lower the costs
of nonhuman primate ART research.
Preservation of gametes
Protocols for cryopreserving macaque semen appear to be
satisfactory insofar as they allow IVF to occur with frozen/
thawed spermatozoa. Several methods are in use, includ-
ing pelleting on dry ice and equilibrium freezing in straws
[7]. However, there is clearly substantial individual donor
variability. The old animal science adage that "some bulls
[semen!] don't freeze" applies also to nonhuman pri-
mates, and perhaps to humans as well. This indicates that
current methods for semen cryopreservation are subopti-
mal, and perhaps need to be customized so that semen
from virtually any individual can be cryopreserved. The
impact of genetic variation on sperm cryopreservability
needs further investigation, from the perspectives of both
basic science and practical applications of technology.
In contrast, current success with oocyte cryopreservation
in primates (nonhuman and human) is poor. Much more
work is needed on this topic. The metaphase spindle in
primate oocytes is very sensitive to cooling, which causes
spindle disassembly and chromosome dispersion [8,9].
There is an urgent need to devise efficient protocols for
primate oocyte cryopreservation, because of its impor-
tance to ARTs in both nonhuman primates (breeding,
gene banking, production of research materials) and in
humans (PCOS patients, postponing childbearing, etc.).
Such protocols can be developed empirically in human
clinical laboratories but more basic science is needed to
optimize these procedures, and here is a major opportu-
nity for research efforts with nonhuman primates. As well
as studying the effectiveness and reliability (preservation
of viability) of oocyte cryopreservation protocols, thePage 3 of 7
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involve the production and destructive analysis of
embryos from cryopreserved oocytes, so once again the
nonhuman primate model is indicated.
In vitro fertilization and embryo production
Several of the National Primate Research Centers have
established IVF programs in macaques, mostly using rhe-
sus monkeys. Present technology for macaque IVF appears
to be adequate, with rates of fertilization and subsequent
embryo development, about the same as for human ART.
However, production of cleavage stage embryos or blasto-
cysts does not necessarily mean that they are all compe-
tent. Some of them are viable, as evidenced by births of
offspring after transfer of IVF embryos. Several NPRCs
reported ART success (production of live offspring) rates
of up to 50%. However, as in human ART, this is accom-
plished by judicious selection of embryos for transfer. The
overall ART process is inefficient, because many embryos
stop developing during cleavage or especially at the
morula-blastocyst transition. The reason for this is
unknown, but either defective oocytes are responsible
and/or present embryo culture media are suboptimal for
supporting normal development. This situation mirrors
that in human ART, where it is difficult to reconcile
research on embryo development with the primary goal of
achieving pregnancy in the patient. Thus, here there is a
major opportunity for research in nonhuman primates to
help improve human ART outcomes.
Embryo transfer
While the rhesus monkey in several ways is an excellent
model for development of ARTs, it suffesr from the disad-
vantage that the tortuous cervical canal is hard to cannu-
late, making uterine embryo transfer difficult. As a result,
in most studies involving embryo transfer, IVP embryos
were inserted into the oviducts, either by a "mini-laparot-
omy" approach [10] or by laparoscopy [11]. Remarkably,
blastocysts have been inserted into rhesus oviducts with
production of live offspring [12], indicating that ectopic
pregnancy in this species is not a concern and also that
transportation of embryos into the uterus by this route is
efficient and rapid. Moreover, this and similar studies
show that the rhesus macaque is capable of carrying twins
to term, unlike with natural breeding, and this offers some
significant advantages for ARTs including the production
of identical twins, which almost never occurs naturally. A
major advantage with nonhuman primates is that embryo
transfers are usually done using surrogate females, so
adverse effects of ovarian stimulation on the recipient's
endocrine status and uterine physiology, as documented
in humans, e.g. [13], are avoided.
Because nonhuman primate ART is primarily a research
area, there is much less emphasis on embryo transfers as
the objective, just the opposite of the situation in humans.
As a result, a total of only ~100 monkeys are reported to
have been born by ART vs. >1 million humans worldwide.
Specialized models for disease research
A key goal that so far has been elusive is the production of
identical macaque monkeys, which occurs naturally
hardly ever, if at all. Availability of identical monkeys
would help disease research and vaccine production
efforts by allowing controls and treatments (e.g., infected
animals) to be compared directly, avoiding the usual
between-animal variations. Use of identical monkeys
would reduce the numbers of animals normally required
for a comparative research study, thus lowering the cost.
Several approaches for making identical monkeys have
been tried. Nuclear transfer using embryonic cells (blast-
omeres) is restricted because so few donor cells are avail-
able from each embryo. Somatic nuclear transfer (SCNT)
seems unlikely to work routinely because in other animals
large numbers of oocytes are required to overcome the
low efficiency of SCNT and this is not an option in mon-
keys. Two potentially viable approaches are morula or
blastocyst splitting, which has been moderately successful
in domesticated animals, and blastomere disaggregation/
reaggregation. A report at this symposium revealed an
inherent flaw in the latter approach that will most likely
preclude success. When pairs of identical rhesus monkey
embryos were produced by blastomere disaggregation,
the number of inner cell mass cells was halved. Although
this number was probably still adequate for viability, pro-
duction of identical twin offspring would require 100%
survival following embryo transfer, which is unlikely to
happen given present success rates. If instead of two, four
identical embryos were produced by this technique, then
only two of them need survive to term to produce identi-
cal offspring, but unfortunately the number of ICM cells
in each blastocyst (1/4 normal) was most probably too
low to develop into a viable fetus.
Instead of relying so heavily on the rhesus macaque for
research into human infertility and disease, it was pointed
out that some other nonhuman primates are also being
used or should be developed as models for ART studies.
While rhesus monkeys are good models for implantation
and pregnancy immunology, embryological studies could
also be done with other macaque species or with vervets
(African green monkeys). Advantages of vervets are that
they are relatively free of dangerous pathogens compared
to rhesus monkeys, and less expensive. The baboon is
excellent for studying normal physiology of pregnancy
and disease (e.g., endometriosis). It would be useful to
develop IVP protocols for this animal so that preimplan-
tation events could also be examined. In any research
study, the importance was emphasized of integrating cel-
lular, endocrine and molecular approaches. It was alsoPage 4 of 7
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great strength of using an experimental animal like a non-
human primate is that it allows hypothesis testing, unlike
most clinical ART studies in humans.
There is also considerable interest in creating transgenic
nonhuman primate models for disease studies. This
approach would allow creation of models with a specific
disease, or amplification of existing models, e.g., nonhu-
man primates with Krabbé disease. Research could then
identify genes responsible for the disease process, leading
to better understanding of mechanisms, and possibly
development of specific treatments. With respect to gene
therapy, nonhuman primate research should play a criti-
cally important role before human clinical trials are
undertaken. Nonhuman primate ARTs would play a key
role in creation of such disease models, e.g., by transfec-
tion of embryos. However, several difficulties inherent
with transgenic nonhuman primates were discussed.
Because nonhuman primates are outbred, genetic varia-
bility will influence the effects of transgenes. This could be
avoided by making identical animals, as described above.
Also, it takes several years before macaques reach puberty,
making it difficult to study an adult onset diseases. This
drawback could be partly offset by targeting X chromo-
some genes. Particular problems in gene targeting have
been encountered in nonhuman primates but creative
solutions are being applied to overcome these. The poten-
tial importance of "knockout" rhesus monkeys was
emphasized, as availability of such animals would help
"level the playing field" with mouse genetic models.
I think it is important to recognize that, if ARTs are used
to generate nonhuman primates with specific disease
traits, then care of the resulting animals may become a
pressing issue because they may need more medical atten-
tion, special housing, etc., than normal animals.
Contraceptive development
This area offers a major role for nonhuman primate ART,
not only for assessing contraceptive effectiveness but also
for establishing new approaches to contraception, by con-
trolling the process of embryogenesis. It is also an area in
which studies with non-primate species are much less
likely to be useful or informative because of the wide dif-
ferences in reproductive strategies (physiology and endo-
crinology) among mammals. Several research
opportunities for nonhuman primates are presented: con-
traceptive research efforts could focus on spermatozoa,
oocytes and fertilization, embryo development or attach-
ment and implantation. The problem of human over-
population, like that of infertility, is global but much
more of a challenge because of the repercussions for the
entire planet. The point was made that there is an urgent
need for new contraceptive approaches, and it is clear that
this is a vastly underemphasized problem. The case was
also made that contraception research is likely to increase
understanding of normal reproductive physiology and
embryology in primates.
Embryonic stem cells in nonhuman primates
Monkey ES cells can provide huge opportunities for stud-
ying basic properties of these primordial cells, and for
developing techniques for directing their differentiation.
These efforts can be sustained without the controversy
that surrounds use of human ES cells, which is restricting
research progress. Several elegant presentations at this
symposium described the remarkable progress being
made with macaque ES cells. Diabetes was described as a
"world wide epidemic" of increasing proportions. There is
an urgent need to develop technology to replace the pan-
creatic beta cells that are defective or lost in diabetic
patients. Using monkey ES cells as a model, it should be
possible to derive beta cells from them in culture, both to
understand the biology of these cells and to devise ways of
creating new pancreatic endocrine tissue. The twin prob-
lems of ES cell technology were described: how to prevent
their spontaneous differentiation in culture, and how to
direct their terminal differentiation into specific pheno-
types, such as functional neuronal cells. Mouse feeder cell
layers have frequently been used to support ES cell cul-
tures, which raises a concern about introducing viruses
into the ES cell products.
One aspect of ES cell production and technology that
appears to be in need of more attention is their cytogenet-
ics. Human ES cell lines have been derived from IVP blas-
tocysts that came from infertile patients and were rejected
for embryo transfer. Moreover, it is well known that 50%
or even more of IVP human embryos are aneuploid to
some degree [14]. Aneuploidy frequencies in macaque
blastocysts have hardly been examined, if at all. Therefore,
there should be considerable concern about the normality
of primate ES cells: if they are cytogenetically abnormal,
then it is hardly likely that they will produce functionally
normal organs and tissues. Appropriate markers also need
to be identified to discriminate cells that are functionally
competent from those that are not. The major issue was
also raised of how to avoid immune rejection following
transplantation of organs generated from ES cells. It seems
that all of these issues could well be, and perhaps should
be, addressed by thorough research in nonhuman pri-
mates prior to efforts in humans. The quality of informa-
tion on monkey ES cells presented at this symposium,
including the high level of homology between monkey
genes and human gene chips, certainly validates this
approach.
One intriguing approach is to use parthenogenetic ES
cells, which appear to be pluripotent. They can differenti-Page 5 of 7
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exhibit some functional properties characteristic of "true"
ES cells. It is questionable whether this useful approach
could be used in humans in the present climate. Even
though parthenogenetic embryos have not been fertilized,
they may still be viewed as "human embryos" and there-
fore still controversial. If so, then the case for using non-
human primate ES cells generated by ART is further
strengthened.
Summary – remaining needs and the future
Several key issues in nonhuman primate ARTs were high-
lighted by this symposium, or arose during discussions. In
addition, as requested by the organizers, I have included a
few of my own thoughts for consideration. It was claimed
that nonhuman primate ARTs "are ready for propagation
of selected genotypes." Certainly, there have been large
improvements in ART success rates, but implantation
rates after embryo transfer are still only about 20%, which
is the same as for human ART [5], so there is considerable
room for increases in primate ART efficiency.
• The production of identical twins in rhesus monkeys
remains problematic. Success would provide a boost to
biomedical research involving nonhuman primates.
There needs to be continued extension of nonhuman pri-
mate ARTs into addressing human disease problems, not
only human infertility.
• We need continued development of technologies sup-
porting these studies, i.e., ES cell derived cells and tissues,
gene chips, etc.
• I think it is very desirable to support cooperative training
and collaborations among primate researchers, especially
those not located at the National Primate Research Cent-
ers. Supplying materials for those investigators, e.g., cryo-
preserved IVP embryos, will increase the amount of
research that can be conducted with nonhuman primates
without large increases in cost, so it becomes more cost-
effective.
• I would encourage the provision of collaborative grants,
using (e.g.) the Cooperative Agreement UO1 mechanism,
to support and stimulate interactive ART research projects
with nonhuman primates. This could be via a joint NCRR/
NICHD/GMS program to share the cost and broaden the
research scope.
• There is a great need for increased emphasis on funding
for nonhuman primate ARTs. Most of the available
research funding during the past two decades has gone to
support studies with mice, and although much basic
information has been generated in this way, very little has
been accomplished that can be directly helpful to human
ART.
• Meetings like this symposium are invaluable and cost-
effective. They bring together researchers from different
areas of nonhuman primate biology and encourage col-
laborations. It would be productive to hold such meetings
regularly, with NIH support.
• There are a number of important research needs that
remain to be addressed, some of which were not directly
addressed in the symposium, including:
(i) Development of protocols for in vitro maturation
(IVM) of primate oocytes; this would be useful for ARTs in
monkeys and for humans, e.g., PCOS patients. This
approach could also avoid excessive ovarian stimulation
that may impact oocyte quality and can disturb the repro-
ductive cycle.
(ii) Identification of non-invasive markers for oocyte and
embryo quality.
(iii) Development of chemically defined embryo culture
media, i.e., without serum or serum proteins, which
would avoid the potential introduction of serum-derived
pathogenic organisms. This could be critically important
for culture of ES cells.
(iv) Obtaining genetic and physiological data on in vivo
produced embryos to establish a normal database for
improving IVP embryo quality; because this is not, and
will not be, available for humans, use of the nonhuman
primate can provide critically important information.
(v) Unless there is a sudden reduction in the AIDS
research emphasis on rhesus macaques, which appears
unlikely, we urgently need to establish other nonhuman
primate models for ARTs. This should be a priority both
for scientists involved in ARTs and for the NIH.
Finally, I suggest that we need to make greater efforts to
educate the general public as well as the federal
government about the value of nonhuman primates as
models for human disease. This could make our work
more appreciated and encourage more support for this
important research area.
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